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Background: The use of food-grade Lactic Acid Bacteria (LAB) as DNA delivery vehicles represents an attractive
strategy to deliver DNA vaccines at the mucosal surfaces as they are generally regarded as safe (GRAS). We
previously showed that either native Lactococcus lactis (LL) or recombinant invasive LL expressing Fibronectin
Binding Protein A of Staphylococcus aureus (LL-FnBPA+) or Internalin A of Listeria monocytogenes (LL-InlA+), were
able to deliver and trigger DNA expression by epithelial cells, either in vitro or in vivo. InlA does not bind to its
receptor, the murine E-cadherin, thus limiting the use of LL-InlA+ in in vivo murine models. Moreover, FnBPA binds
to its receptors, integrins, via fibronectin introducing another limiting factor. In order to avoid the limitations of
LL-InlA+ and LL-FnBPA+, a new L. lactis strain was engineered to produce a previously described mutated form of
InlA (LL-mInlA+) allowing the binding of mInlA on murine E-cadherin.
Results: After showing the expression of mInLA at the surface of LL-mInlA+ strain, in vitro gentamycin survival
assay in Caco-2 cells showed that LL-mInlA+ is 1000 times more invasive than LL. LL-mInlA+ invasivity was also
validated by fluorescence microscopy. LL and LL-mInlA+ were transformed with pValacBLG, a plasmid containing
the cDNA of bovine β-Lactoglobulin (BLG), resulting in strains LL-BLG and LL-mInlA+BLG. The plasmid transfer
in vitro using LL-mInlA+BLG was increased 10 times compared to LL-BLG. Moreover, the number of mice producing
BLG in isolated enterocytes after oral administration of LL-mInlA+BLG in vivo was slightly higher than after oral
administration of LL-BLG.
Conclusions: We confirmed in this study that the production of mInlA at the surface of L. lactis is a promising
strategy for plasmid transfer in vitro and in vivo.
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DNA vaccination has gained a lot of attention since its
ability to induce long-lasting humoral and cellular im-
mune responses against an encoded antigen was discov-
ered [1]. In addition, DNA vaccination poses no danger
of integration into host cellular DNA thereby raising its
safety profile [2-4]. DNA vaccines can be easily isolated* Correspondence: jean-marc.chatel@jouy.inra.fr
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distribution, and reproduction in any mediumto high purity, encode multiple antigens, and possess in-
herent adjuvant activity due to the presence of unmethy-
lated CpG motifs that are recognized in mammals by
TLR9 [5]. So called purified “Naked” DNA vaccination
was shown to be highly efficient in rodents and mice,
but not in larger animals and humans [6]. Consequently,
it is very important to optimize DNA vaccine vectors
and develop a delivery system to facilitate cellular
uptake and enhance gene transfer efficiency and expres-
sion in situ [7].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mids from degradation, facilitating DNA uptake by
phagocytic Antigen Presenting Cells (APCs) and thereby
enhancing their immunological properties. This includes
delivery technologies based on encapsulation into syn-
thetic particles (cationic liposomes or polymers) or the
use of viral vectors [7,8]. Despite their potential, some
limitations and safety issues still remain which can re-
strict the application of gene therapy - e.g. the complex-
ity of producing liposomes and their limited packaging
capacity [9]. Additionally, it was shown that some viral
vectors have the capacity to randomly integrate their
genetic material into the host genome causing inser-
tional mutagenesis of a cellular oncogene, leading to
tumour formation [10].
The use of bacteria as delivery vehicles for DNA vac-
cination has emerged as an interesting alternative to
overcome many of the problems associated with viral or
liposomal delivery [11]. W. Schaffner was the first to ob-
serve genetic material transfer from bacteria to mamma-
lian cells [12]. Since then, bacteria have been extensively
exploited as vaccine delivery vehicles for vaccination
against bacterial and viral pathogens as well as cancer
immunotherapy [13-15]. The use of bacteria for mucosal
delivery of DNA vaccines may be advantageous due to
their potential to elicit secretory IgA responses as well
as systemic immunity, when compared to conventional
parenteral immunization [16]. Furthermore, bacterial
carriers can increase and expand the magnitude of im-
mune responses against the vector-encoded antigen due
to the natural presence of Pathogen-Associated Molecu-
lar Patterns (PAMPs) that bind to Toll-like receptors
(TLRs) and activate immune cells [5].
Presently, attenuated pathogens such as Salmonella,
Shigella, Listeria, Yersinia, as well as, non-pathogenic
Escherichia coli have been used as experimental live de-
livery systems [17,18]. An advantage of using attenuated
pathogens as DNA vaccine vehicles is that they possess
mechanisms to adhere or invade host cells with a negli-
gible risk of reversion to a virulent strain via gene trans-
fer or mutation. However, a potential concern is the risk
of increased virulence in young or immunocompromised
individuals.
The use of food-grade lactic acid bacteria (LAB) as
DNA delivery vehicle represents an alternative and at-
tractive strategy to deliver DNA vaccines at the mucosal
surfaces (ref review by 19 and 20). The dietary group of
LAB, including Lactococcus lactis and many species of
Lactobacillus, is generally regarded as safe (GRAS)
organisms of which some are intestinal commensals of
humans. Indeed, it has been extensively demonstrated
that these bacteria are able to deliver a range of vac-
cine and therapeutic molecules for applications in aller-
gic, infectious or gastrointestinal diseases [19,21,22]. Arelatively new development, however, is their use as a
vehicle for genetic immunization [23]. Previous ex-
periments performed by our group showed that either
native L. lactis (LL) or recombinant invasive LL ex-
pressing Fibronectin Binding Protein A (LL-FnBPA+) of
Staphylococcus aureus or Internalin A (InlA) of Listeria
monocytogenes (LL-InlA+) [24,25], were able to deliver
DNA in epithelial cells both in vitro and in vivo, dem-
onstrating potential as gene transfer vehicles [24-27].
However InlA does not bind to its murine receptor, E-
cadherin, thus limiting the use of LL-InlA+ in in vivo
murine model. On the other hand, FnBPA requires an
adequate local concentration of fibronectin to bind to its
receptors, integrins [28,29].
In order to avoid the limitations of InlA and FnBPA
and improve our knowledge on the key steps by which
the DNA is transferred to mammalian cells using L. lac-
tis, LL was engineered to express a mutated form of
Internalin A (mInlA; Ser192Asn and Tyr369Ser) that
increased binding affinity to murine and human E-
cadherin [30,31] thus allowing for in vivo experiments in
conventional mice. Herein, we describe the construction
and characterization of this novel L. lactis strain as a
DNA delivery vector, using cow’s milk β-lactoglobulin
(BLG) allergen, to measure DNA transfer to intestinal
epithelial cells (IECs) in vitro and in vivo.
Overall, the production of mInLA+at the surface of
Lactococcus lactis increased the invasisity of bacterium
and amount of plasmid transfer by 1000 and 10 fold, re-
spectively. In vivo, BLG production was detected in iso-
lated enterocytes after oral administration of LL-mInlA
+BLG and was slightly higher than oral administration
of LL-BLG.
Results
Mutated internalin A is produced on the surface of
recombinant L. lactis strain
To investigate surface expression and production of
mInlA, L. lactis NZ9000 and LL-mInlA+ strains were
incubated with specific anti-mInlA monoclonal antibody
and then with FITC-conjugated anti-Mouse IgG. Stained
cells were analyzed by flow cytometry. As shown in
Figure 1, LL-mInlA+ strain (blue peak) showed a signifi-
cant shift in the fluorescence intensity comparing to the
NZ9000 strain (black peak). No shift was observed when
strains were incubated with FITC-labeled anti-Mouse
IgG alone (data not shown). This experiment confirmed
expression of mInlA on the surface of L. lactis.
L. lactis producing mInlA is efficiently internalized by
Caco-2 cells
Non-confluent Caco-2 cells were incubated for 1 h with
either NZ9000 or with LL-mInlA+. Non internalized






Figure 1 Characterization of mInlA production at the surface of
L. lactis. Black peak corresponds to the negative control, the wild
type strain (LL) and the blue peak corresponds to L. lactis strain
producing mInlA (LL-mInlA+).
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The LL-mInlA+ strain exhibited 1000-fold greater inva-
sion rate than NZ9000 strain (Figure 2).
LL-mInlA+ internalization analyzed by confocal
microscopy
LL-mInlA+ and NZ9000 strains were labeled with CFSE
dye and then incubated with Caco-2 cells for 1 h. Cells











Figure 2 Evaluation of the LL-mInlA+ invasiveness capacity in
non-confluent Caco-2 cells. Caco-2 cells were co-incubated with
NZ9000 and LL-mInlA+ strains during 1 h and then treated with
gentamicin for 2 h. Cells were lysed and the number of CFU
internalized was measured by plating. **, survival rates were
significantly different (One-way ANOVA, Bonferroni’s multiple
comparison test, p < 0.05). Results are means standard deviations of
three different experiments, each time done in triplicate.cell-associated bacteria could be detected after co-
incubation with NZ9000 (Figure 3A). In contrast, the
LL-mInlA+ strain strongly bound to the membrane of
cell clusters which is compatible with the known binding
of InlA to E-cadherin, a cell-cell adhesion molecule. In
addition, LL-mInlA+ was located intracellularly in some
cells (Figure 3C and B).
LL-mInlA+ can efficiently deliver in vitro a DNA vaccine
containing β-lactoglobulin cDNA
To test the ability of LL-mInlA+ to deliver a DNA vac-
cine plasmid in vitro to IECs, we transformed LL-mInlA
+ strain with pValac:BLG [32], a plasmid derived from
pValac [23] containing the cDNA for BLG, under the
control of an eukaryotic promoter to generate strain LL-
mInlA+BLG (Table 1).
In order to monitor plasmid transfer and production
of BLG in Caco-2 cells extracts, non-confluent Caco-2
cells were incubated with noninvasive L. lactis strains,
LL and LL-BLG (see Table 1), or with LL-mInlA+BLG
for three hours. After incubation with these bacteria, cell
supernatant and proteins extracts from Caco-2 cells
were tested for BLG expression using an EIA. BLG pro-
duction was measured in Caco-2 cells protein extracts
incubated with either LL-BLG or LL-mInlA+BLG. How-
ever, incubation with the LL-mInlA+BLG strain resulted
in 10 fold higher levels of BLG compared to LL-BLG
strain demonstrating that surface expression of mInlA
enhanced intracellular delivery of the DNA vaccine
DNA (Figure 4A).
Secreted levels of BLG were increased 2 fold after co-
incubation with LL-mInlA+BLG compared to LL-BLG
(Figure 4B). These data shows that LL and LL-mInlA+,
can mediate gene transfer of a DNA vaccine to Caco-2
cells in vitro and that invasiveness significantly increases
the efficiency of DNA delivery.
DNA delivery efficiency in vivo is slightly improved by the
production of mInlA
Mice were intragastrically administrated with LL, LL-
BLG or LL-mInlA+BLG for three consecutive days, and
the small intestine removed for isolation of IECs. BLG
production was detected in protein extracts from IECs
of mice administered with LL-BLG and LL-mInlA+BLG
but not with control mice (Figure 5). In both of the LL-
BLG and LL-mInlA+BLG treated groups, some mice did
not show production of BLG suggesting that DNA deliv-
ery may be a stochastic event depending on environ-
mental factors. Even if this trend was not statistically
significant, the number of mice producing BLG (in each
of the three individual experiments) was systematically
higher (11 mice) in the group administered with invasive
bacteria than with noninvasive bacteria (8 mice produ-
cing BLG) suggesting that the LL-mInlA+strain is a
Caco-2
LL LL-mInlA+ LL-mInlA+A B C
Figure 3 LL-mInlA+ internalization in Caco-2 cells analyzed by confocal microscopy. NZ9000 and L. lactis producing mutated internalin A
(LL-mInlA+) were stained with CFSE dye (in green) and co-incubated with Caco-2 cells. Cell membranes were stained with DiI cell-labeling
solution (in red) and the fluorescent samples were analyzed by confocal microscopy as described in the methods. 3A. Non-internalization of
NZ9000 strain in Caco-2 cells. 3B. Intracellular localization of LL-mInlA+ in some cells. 3C. LL-mInlA+ bind to the membrane of cell clusters where
mInlA receptor, E-cadherin, is exposed.
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strain.
Discussion
There is a large body of research demonstrating that the
use of L. lactis is able to elicit humoral and cellular im-
mune responses to an antigen produced in rodents (for
reviews see [19-22]).
Recently, we showed the ability of either native or re-
combinant invasive L. lactis as both in vitro and in vivo
DNA delivery vehicle [24-27]. Recombinant invasive L.
lactis strains were obtained by producing heterologous
invasins which are proteins expressed at the surface
of pathogens responsible for their invasivity. We first
built lactococci expressing Internalin A (InlA) from
Listeria monocytogenes (LL-InlA+) and showed that
LL-InlA+ were able to 1) deliver a plasmid in vitro and 2)






NZ9000 A derivative of L. lactis MG1363 wild type strain generated by
LL L. lactis MG1363 containing pOri23 plasmid
LL-mInlA+ L. lactis NZ9000 strain containing pOri253:mInlA
LL-BLG L. lactis MG1363 strain containing pOri23 and pValac: BLG pla
LLmInlA+BLG L. lactis NZ9000 strain expressing mInlA gene and carrying pV
Plasmids
pPL2:mInlA E. coli vector containing mInlA gene
pOri253Link L. lactis-E. coli shuttle vector, Eryr
pOri23 L. lactis-E. coli shuttle vector, Eryr
pValac: BLG L. lactis-E. coli shuttle vector carrying the BLG gene under the
pOri253:
mInlA
L. lactis-E. coli shuttle vector carrying the mInlA gene under th
harboring the native cell wall anchoring signal
Eryr Erythromycin resistant; Cmr Chloramphenicol resistant.Nevertheless, the use of LL-InlA+ is restricted because
InlA does not bind efficiently to its murine receptor, the
E-cadherin [33]. Subsequently, we produced another
invasin, the Fibronectin Binding Protein A (FnBPA) from
Staphylococcus aureus and demonstrated that LL-FnBPA
+ were invasive and able to transfer a plasmid in vitro
more efficiently than non-invasive L. lactis [25]. How-
ever, FnBPA requires an adequate local concentration of
fibronectin in order to bind to its receptors, integrins
[28,29], and this limitation could be a problem in vivo.
So, in this study we produced a mutated Internalin A
(mInlA) at the surface of L. lactis. The two mutations
introduced were demonstrated to allow the binding of
mInlA to murine E-cadherin thus permitting in vivo
experiments with conventional mice [30,31].
We first checked that mInlA was expressed and prop-
erly directed to the surface of L. lactis. The shift of
fluorescence peak obtained for LL-mInlA+ in FACSSource/
reference








control of the eukaryotic promoter IE CMV, Cmr 32







































Figure 4 BLG production in Caco-2 cells after co-incubation with LL-mInlA+BLG or LL-BLG. Caco-2 cells were co-incubated with LL, LL-BLG
or LL-mInlA+BLG during 3 h. BLG was assayed 72 h after co-incubation in cellular protein extracts (A) or medium (B). The results are expressed as
mean ± SE values. Statistical significance between the groups was calculated using the One Way ANOVA followed by the “Bonferroni” post-test.
Values of p < 0.05 were considered significant.
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strain thus confirming successful surface expression of
mInlA on L. lactis. Other invasins, from Gram-positive
bacteria, such as InlA or FnBPA, have already been
successfully expressed in L. lactis confirming that the
signal peptide for secretion and the anchoring signal
are well recognized by the L. lactis machinery. Produc-
tion of invasins from Gram-negative bacteria, such
as Yersinia pseudotuberculosis invasin at the surface of
L. lactis has never been successful (Denis Mariat, per-
sonal communication).
The invasivity was assessed by gentamicin assay in non-
differentiated E-cadherin expressing human epithelial cell
line Caco-2 cells. This experiment showed that LL-mInlA
+strain is 1000-fold more invasive than NZ9000 strain.
Wollert and collaborators (2007) observed a 2-foldin-



















Figure 5 β-Lactoglobulin detection in mice isolated enterocytes
after oral administration of noninvasive and invasive lactococci
strains. Mice were orally administered 3 consecutive days with LL,
LL-BLG or LL-mInlA+BLG. Seventy two hours after the last gavage,
mice were sacrificed and BLG was assayed in protein extracts from
isolated small intestine enterocytes. Results showed the sum of two
independent experiments.monocytogenes strain producing mInlA compared to wild-
type listeria expressing native InlA by using gentamicin-
protection-invasion assays in Caco-2 cells [30]. A confocal
image taken after gentamicin assay showed clearly that
LL-mInlA+ is capable of adhering to and entering in non-
differentiated Caco-2 cells. The preferential distribution of
recombinant bacteria at the periphery of the Caco-2 cell
islets can be explained by the fact that E-cadherin is
accessible only at the periphery. A similar type of bacterial
distribution, around the Caco-2 cell islets, was previously
observed when Caco-2 cells were co-incubated with
LL-FnBPA+[25].
LL-mInlA+ and LL strains were then transformed with
pValac: BLG plasmid, co-incubated with Caco-2 cells
and BLG expression was followed 72 h later by ELISA.
BLG was detected in the cytoplasmic fraction of Caco-2
cells which were co-incubated with noninvasive and in-
vasive strains carrying pValac: BLG. This data confirms
prior observations that even noninvasive L. lactis can
transfer functional plasmids to Caco-2 cells [23]. Cells
were also capable of secreting the allergen, which is
an interesting characteristic facilitating antigen uptake
and presentation by professional APCs through cross-
priming pathways [1]. The use of LL-mInlA+ improved
BLG expression around ten times compared to noninva-
sive strain. Our hypothesis is that invasive lactococci can
enter in higher numbers inside epithelial cells and thus
deliver more plasmids.
Noninvasive and invasive L. lactis, carrying pValac:
BLG or not, were orally administered for 3 consecutive
days in BALB/c mice. On the fourth day, enterocytes
from the small intestine were isolated and BLG produc-
tion was measured by enzyme immunoassay (EIA). Iso-
lated enterocytes from mice administered with invasive
LL-mInlA+BLG produced the same amount of BLG as
compared to mice immunized with noninvasive LL-BLG.
Thus, we confirmed that noninvasive lactococci are able
to transfer a functional plasmid in vivo in mice [27]. The
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mice positive for plasmid transfer. Surprisingly, BLG
production was not increased.
These results partly confirmed what we published re-
cently with LL-FnBPA+BLG in vitro and in vivo [32].
Oral administration in mice of LL-FnBPA+BLG or LL-
FnBPA+GFP elicited a GFP or BLG production in enter-
ocytes. As with LL-mInlA+ the BLG production was not
increased with LL-FnBPA+. However the number of
mice producing BLG was significantly higher after oral
administration of LL-FnBPA+BLG compared to non in-
vasive LL-BLG. Considering these results it seems that
LL-FnBPA+strain is a better DNA delivery vehicle than
LL-mInLA+.
As no significant advantages were observed by using
LL-mInlA+BLG compared to LL-BLG, we hypothesize
that interactions of recombinant mInlA with their recep-
tors were impeded in mouse intestinal epithelium. This
lack of invasion in vivo was also observed by another
group working with E. coli strain expressing invasin
from Yersinia pseudotuberculosis as an oral vaccine for
cancer immunotherapy. They showed that invasive E.
coli was unable to enter gut epithelial cells due to a
basolateral localization of the receptor, B1-integrin [34].
They demonstrated that invasive E. coli expressing Y.
pseudotuberculosis invasin were selectively uptaken from
the intestinal lumen into Peyer’s patches using an
ex vivo model. Similarly, E-cadherin, the mInlA receptor,
is also expressed on the basolateral membrane of IECs
which are strongly linked to each other in the gut mak-
ing E-cadherin less available. It has been shown recently
that L. monocytogenes could enter the epithelial mem-
brane through extruding epithelial cells at the top of the
villi but mainly through goblet cells which are located
deeper in the crypt [35]. It is thus possible that LL-
mInlA+BLG strain is not able to reach its receptor
deeply buried in the crypt. The pathway whereby bac-
teria could penetrate gut epithelial monolayers could be
through Microfold (M) cells in Peyer’s patches. These
cells are able to take up particles/bacteria from the
lumen [36]. Nevertheless, we cannot exclude any possi-
bility that lactococci can also interact with other cells
from the epithelial membrane such as dendritic cells.
Some subset of dendritic cells is now well known to pro-
duce dendrites, able to reach the lumen in order to sam-
ple its content [37].
The other hypothesis is that the plasmid would be
released in the lumen by lysed lactococci and then cap-
tured by the enterocytes. It has been shown that lacto-
cocci do not persist in the gut and are very sensitive to
its physico-chemical condition [38]. Most likely, plasmid
transfer in vivo is a combination of both mechanisms,
bacteria and released plasmid captures. Considering
these data, the use of lactobacilli which persist longer inthe gut than lactococci could be a better option for
DNA delivery.
Conclusions
Mutated Internalin A protein was successfully expressed
at the surface of L. lactis NZ9000, as demonstrated by
FACS analysis. LL-mInlA+ strain was demonstrated to
be 1000 times more invasive as compared to NZ9000
strain. This invasiveness capacity was confirmed by con-
focal microscopy experiments wherein LL-mInlA+ was
found to be attached to Caco-2 cells and intracellularly
located. Assays of BLG detection after BLG expression
by eukaryotic cells revealed that the invasive status
improved plasmid transfer in vitro. In vivo, the number
of mice expressing BLG was higher (n = 11) in the group
immunized with invasive bacteria than with noninvasive
bacteria (n = 8). Even though this difference was not sta-
tistically significant, these study suggests that LL-mInlA
+ strain can be used as a DNA delivery vehicle for
in vitro or in vivo experiments. The use of other LAB
species which can persist longer in the gastrointestinal
tract, such as lactobacilli, to mediate DNA transfer is
currently being evaluated.
Methods
DNA manipulation and plasmids construction
Procedures for DNA manipulation were carried out as
described by Sambrook et al. (1989) [39], with a few
modifications. Plasmids were purified by the alkaline
lysis method after bacterial incubation for 30 min at
37°C in TES solution (25% sucrose, 1 mM EDTA,
50 mM Tris–HCl pH 8) containing lysozyme (10 mg/
ml). The quality of the DNA, including its concentration
and purity, was estimated by measuring the absorbance
at 260 nm and 280 nm in spectrophotometer (Spectra-
Fluor Plus, Tecan). Restriction and modification endonu-
cleases were used according to recommendations of the
suppliers. Details concerning the plasmids used in this
study are found in Table 1.
In order to construct pOri253Link:mInlA, mInlA
gene was excised from pPL2:mInlA vector (9438 bp)
[30] with BamHI and NotI restriction enzymes
and gel purified generating a 3000 bp DNA fragment.
pOri253Link plasmid (5857 bp) was derived from
pOri253 [40] by modifying the multiple cloning site.
Two complementary oligos CCGGGGGATCCTCGA
GACGCGTCCATGGCGGCCGCTGCA and CCCTAG
GAGCTCTGCGCAGGTACCGCCGGCG introducing
the following restriction sites, BamhI, XhoI, MluI, NcoI
and NotI were annealed and ligated into pOri253 previ-
ously digested with XmaI and PstI (underlined). BamHI/
NotI-digested and purified pOri253Link and mInlA
fragments were ligated using T4 DNA ligase (Invitrogen)
to obtain pOri253:mInlA vector (9175 bp) (Table 1).
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and in L. lactis NZ9000 strain as described in the next
section.
Bacterial strains, media and growth conditions
Bacterial strains are listed in Table 1. Briefly, L. lactis
NZ9000 strain were grown in M17 medium containing
0.5% glucose (GM17) at 30°C without agitation and
10 μg/ml of erythromycin (Ery) or 5 μg/ml of chloram-
phenicol (Cm) were added, when required. Electropor-
ation of L. lactis NZ9000 with pOri253:mInlA and/or
pValac: BLG [32] plasmids was performed as described
by Langella et al. (1993) [41]. Transformants were plated
on GM17 agar plates containing Ery or Cm at the same
concentration mentioned above and incubated at 30°C
for two days before subsequent freezing or colony form-
ing unit (CFU) counting. Positive clones were confirmed
by colony PCR using specific oligos.
Mice handling
Specific pathogen-free BALB/c mice (females, 6 weeks
of age; Janvier, France) were maintained under normal
husbandry conditions in the animal facilities of the
National Institute of Agricultural Research (UEAR,
INRA, Jouy-en-Josas, France). All animal experiments
began after allowing the animals 1 week for acclimation
and were performed according to European Community
rules of animal care and with authorization 78-149 of
the French Veterinary Services.
Detection of mInlA expression by L. lactis using flow
cytometry analysis
L. lactis NZ9000 and recombinant L. lactis expressing
mInlA were centrifuged (5000 rpm), washed with phos-
phate buffered saline (PBS) and then resuspended at a
concentration of approximately 1x109 CFU/ml in 500 μl
of PBS containing 0.5% of bovine serum albumin (BSA)
and 10 μg/mL of monoclonal antibody anti-InlA kind-
ly provided by Dr. Pascale Cossart (Cell Biology and
Infection Department/Unité des Interactions Bactéries-
Cellules, Pasteur Institute, Paris). After one hour incuba-
tion at 4°C, the bacteria were pelleted by centrifugation
washed with PBS and then resuspended in 500 μl of PBS
plus 0.5% of BSA containing fluorescein isothiocyanate
(FITC)-conjugated AffiniPure Fab fragment Goat Anti-
Mouse IgG (H+L) (Jackson Immuno Research). After 1 h
incubation at 4°C, bacteria were washed once more with
PBS and fixed in 2% paraformaldehyde for 30 min at 4°C.
FITC labeled antibody binding to InlA was assessed by
flow cytometry (Accuri C6 Flow CytometerW) using exci-
tation at 494 nm and emission in the range of 510-530 nm
(FL1-A channel). Data analysis was performed using
CFlow Software (Accuri Cytometers, Inc.). The result wasexpressed as the average of three independent experi-
ments performed in triplicate.Invasion assay of bacteria into intestinal epithelial cells
The human intestinal epithelial cell line Caco-2 (ATCC
number HTB37) derived from a colon carcinoma was
used to measure invasion capacity of each strain. Caco-2
cells were cultured in RPMI medium containing
2 mM L-glutamine (BioWhittaker, Cambrex Bio Science,
Verviers, Belgium) and 10% fetal calf serum in p-24
plates (Corning Glass Works) until they reached 70-80%
confluence. In the assays on non-confluent Caco-2 cells,
approximately 4x105 cells were present in each p-24
well. Bacterial strains were grown to an OD600 of
0.9–1.0, pelleted and washed in PBS, then added to the
Caco-2 cell cultures at a multiplicity of infection (MOI)
of approximately 1000 bacteria per eukaryotic cell. The
gentamicin survival assay was used to evaluate bacteria
survival. In summary, recombinant or wild type L. lac-
tis were applied in the apical side of eukaryotic cells
and co-incubated during one hour at 37°C, in 5% CO2.
After this period, cells were washed in order to re-
move bacteria in excess and then 150 μg/mL of genta-
micin was added for 2 h to kill the extracellular
bacteria. Cells were then lysed with 0.2% triton-X
100 diluted in water. Finally, serial dilutions of the
cell lysate were plated for bacterial counting. CFU of
intracellular bacteria were expressed as the average
of three independent gentamicin assays performed in
triplicate. Invasion rate was calculated as the ratio of
CFU counts.Confocal laser scanning
Bacteria were stained as described by Lee et al. (2004)
[42]. Stationary phase culture of recombinant or wild
type L. lactis, were washed twice in PBS and stained with
50 μM of green fluorescent dye carboxyfluorescein suc-
cinimidyl ester (CFSE) at 37°C for 20 min under con-
stant shaking in the dark. CFSE labeled bacteria were
used to perform the invasion assay as described above
in non-differentiated Caco-2 cells grown on filter
inserts. After 1 h of infection, cells were washed three
times with PBS and fixed using 4% paraformaldehyde.
Cell membranes were stained with 1 μM VybrantW
CM-DiI cell-labeling solution (Invitrogen) for 1 h at
room temperature. Cells were mounted in Vectashield
solution (Vector Labs, Burlingame, USA) to minimize
photobleaching. Confocal images were obtained using a
Zeiss LSM 510 system consisting of a Zeiss Axioskop
with a Zeiss Plan Neofluar 63x NA 1.3 oil objectives.
Stacks of images were reconstructed using Zeiss LSM
software.
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In order to measure BLG expression and secretion by
human epithelial cells the gentamicin survival assay was
performed with Caco-2 cells as described above, how-
ever, bacteria and Caco-2 cells were incubated for three
hours. After gentamicin treatment, plates were main-
tained for 72 h at 37°C, in 5% CO2. Supernatant was col-
lected by centrifugation at 78.2 g (800 rpm) for 10 min
and stored at -80°C. One mL of PBS supplemented with
a cocktail of protease inhibitors (Roche) was then homo-
genized by sonication (3 times 10 s). Samples were kept
at -80°C and used to measure BLG production using an
Enzyme ImmunoAssay (EIA) described in the next
section.
Enzyme immunometric assay (EIA) for quantification of
bovine β lactoglobulin in human epithelial cells
The method used for BLG quantification is described
elsewhere [43]. In summary, 96 microtitre plates were
coated with 3.5 μg/ml of anti-BLG monoclonal antibody,
diluted in 50 mM phosphate buffer (PB) pH 7.4, and
incubated overnight at room temperature. After wash-
ing, plates were blocked with EIA buffer (0.1 M PB pH
7.4; 1 g/1 L BSA; 0.15 M NaCl; 0.001 M Na2EDTA;
0.1 g/1 L sodium azide) and stored sealed at 4°C until
use. Standard (recombinant BLG) and samples diluted in
EIA buffer were added and kept at 4°C for 18 h. After
this time, plates were extensively washed and then
acetylcholinesterase conjugated monoclonal anti-BLG
antibody (1 Ellman Unit/ml) was added for 18 h at 4°C.
After washing, Ellman reagent was added and enzymatic
reaction was measured at 405 nm in a spectrophotom-
eter (SpectraFluor Plus, Tecan).
Oral administration of mice
Conventional BALB/c mice, 3 to 6 weeks of age were
purchased from INRA animal care facilities (Jouy-en-
Josas, France), acclimatized for 1 week before
immunization under standard animal husbandry condi-
tions in the animal facility (Unité d'Expérimentation
Animale, Jouy-en-Josas, France). Mice (n = 8) were intra-
gastrically administered with 1x109 (CFU) of strains, LL,
LL-BLG or LLmInlA-BLG on 3 consecutive days using a
gavage tube feeding. On the fourth day, the small intes-
tine was collected for subsequent BLG quantification in
isolated IECs.
Intestinal epithelial cells isolation
Mice were euthanized, and their small intestines were
removed, rinsed with complete DMEM medium (con-
taining 2 mM L-glutamine and 10% fetal calf serum).
The length of intestine was opened and submerged in
buffer A (in mM: 120 NaCl, 4.7 KCl, 2.4 KCl, 1.2KH2PO4, 1.2 Na2HP04, 25 NaHCO3, 10 HEPES, 5
EDTA, 0.5 DTT, 0.25% BSA; at pH 7.4 warmed to 37°C)
for 20 min with agitation at 240 rpm [44]. Cells were
collected by centrifugation (415.73 g – 2000 rpm – for
5 min) at room temperature, washed once with PBS and
lysed by sonication (3 times, 10 s). The cell lysate was
centrifuged for 10 min at 3143.98 g (5500 rpm), then the
supernatant was recovered and stored at -80°C. The EIA
to detect BLG was performed as described above.
Statistical analyses
The results are expressed as mean ± standard error (SE)
values. Statistical significance between the groups was
calculated using the One Way ANOVA (and nonpara-
metric) test, followed by the “Bonferroni” post-test.
Values of p < 0.05 were considered significant.
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